Joshua Brumm
2019 - Kaleido Biosciences
In 2019, Joshua Brumm earned a total compensation of $1.1M as Chief Operating Officer and Chief Financial Officer former principal financial officer at Kaleido Biosciences, a 61% decrease compared to previous year.
Compensation breakdown
| Option Awards | $747,200 |
|---|---|
| Salary | $349,916 |
| Other | $764 |
| Total | $1,097,880 |
Brumm received $747.2K in option awards, accounting for 68% of the total pay in 2019.
Brumm also received $349.9K in salary and $764 in other compensation.
Rankings
In 2019, Joshua Brumm's compensation ranked 8,845th out of 13,971 executives tracked by ExecPay. In other words, Brumm earned more than 36.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,845 out of 13,971 | 37th |
Division Manufacturing | 3,528 out of 5,701 | 38th |
Major group Chemicals And Allied Products | 1,335 out of 2,200 | 39th |
Industry group Drugs | 1,137 out of 1,886 | 40th |
Industry Biological Products, Except Diagnostic Substances | 256 out of 389 | 34th |
Source: SEC filing on May 8, 2020.
Brumm's colleagues
We found four more compensation records of executives who worked with Joshua Brumm at Kaleido Biosciences in 2019.
News
Dyne Therapeutics CEO Joshua Brumm's 2022 pay rises 6% to $4.3M
April 7, 2023
Dyne Therapeutics CEO Joshua Brumm's 2021 pay falls 66% to $4.1M
April 22, 2022
Dyne Therapeutics CEO Joshua Brumm's 2020 pay jumps 981% to $12M
April 14, 2021
Kaleido Biosciences CEO Alison Lawton's 2019 pay falls 57% to $2.9M
May 8, 2020